Desoxypipradrol
| Clinical data | |
|---|---|
| Routes of administration | By mouth, nasal and sublingual |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Bioavailability | >90% |
| Metabolism | Liver |
| Elimination half-life | 16–20 hours |
| Identifiers | |
| |
| CAS Number |
|
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.007.525 |
| Chemical and physical data | |
| Formula | C18H21N |
| Molar mass | 251.373 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
| (verify) | |
Desoxypipradrol, also known as 2-diphenylmethylpiperidine (2-DPMP), is a drug developed by Ciba in the 1950s which acts as a norepinephrine-dopamine reuptake inhibitor (NDRI).